The Prostate Cancer Foundation today announced that it is funding two more Young Investigators in China to lead innovative research projects within the country and expand PCF's global knowledge exchange on game-changing research in prostate cancer.
[More]
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone (TOK-001), Tokai's lead prostate cancer drug candidate.
[More]
Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.
[More]
An international group of investigators, led by researchers at Thomas Jefferson University's Kimmel Cancer Center, have solved the mystery of why a substantial percentage of castrate-resistant metastatic prostate cancer cells contain abnormally high levels of the pro-growth protein Stat5.
[More]
The Prostate Conditions Education Council, a national organization committed to men's health and a leader in prostate cancer early detection, released the following statement in response to new clinical practice guideline released today by the American Urological Association.
[More]
The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.
[More]
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.
[More]
US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.
[More]
Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting.
[More]
Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.
[More]
The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.
[More]
The relationship between obesity and polycystic ovary syndrome may be exaggerated, likely because the women who actively seek care for the condition tend to be heavier than those identified through screening of the general population, researchers report.
[More]
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
[More]
Angela H. Brodie, Ph.D., a University of Maryland scientist whose research paved the way for a new class of drugs widely used to treat breast cancer patients around the world, has been selected by the American Association for Cancer Research as a fellow of the newly created AACR Academy.
[More]
DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.
[More]
Despite the high erectile dysfunction prevalence most patients receive no treatment, according to a new US study, presented at the 28th Annual EAU Congress. Undertreatment of ED continues to be common, even though the treatments have a proven efficacy and quality of life impact.
[More]
As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).
[More]
GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.
[More]
Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.
[More]
Androgen deprivation therapy for prostate cancer hampers glycemic control in men with diabetes, report researchers.
[More]